BioInvent International AB has signed a manufacturing agreement with an undisclosed U.S. cell therapy company for the production of cGMP compliant material to support their clinical development programs.   The manufacturing agreement is expected to generate revenue of approximately $1.5 million, mainly in 2019.   BioInvent is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The company’s lead program is BI-1206, currentl...